The efficacy of cetuximab plus PD-1 inhibitors as salvage therapy in PD-1 refractory patients with recurrent or metastatic head and neck squamous cell carcinoma.

导出 OA

翻译打印收藏纠错

第一作者： Rongrong,Hui

第一单位： School of Stomatology, Weifang Medical University, Weifang, China.

作者： Rongrong,Hui ^[1] ; Xiulan,Liu ^[2] ; Zongyu,Fan ^[2] ; Honghai,Ji ^[2] ; Dongliang,Wei ^[1] ; Guoxin,Ren ^[2]

作者单位： School of Stomatology, Weifang Medical University, Weifang, China. ^[1] Department of Oral Maxillofacial-Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. ^[2] Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology; National Clinical Research Center of Stomatology, Shanghai, China. ^[3]

关键词 cetuximab programmed cell death protein 1 (PD-1) immunotherapy recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)salvage therapy

DOI 10.7150/jca.92689

PMID 38370365

发布时间 2024-02-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交